ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1931

MRI Findings in Granulomatosis with Polyangiitis: Pachymeningitis and Implications in Quality of Life

Violeta Higuera-Ortiz1, Natllely Ruiz1, Daniel Carrillo2, Abraham Reynoso2, Rosa Delia Delgado-Hernández2 and Luis F. Flores-Suarez1, 1Primary Systemic Vasculitides Clinic, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, 2Radiology and Molecular Imaging, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: ANCA, central nervous system involvement, magnetic resonance imaging (MRI) and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Vasculitis - Poster II: ANCA-Associated Vasculitis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The frequency of CNS involvement in granulomatosis with polyangiitis (GPA) is uncommon (4-18%). Among them, pachymeningitis (PM) has been reported in 0.6-8%. Improvement of these complications has been reported with conventional therapy (CS + CYC), and recently with rituximab, but many patients have recurrences. Data on related factors, outcome and quality of life is scarce. We preliminarily describe CNS involvement as investigated with MRI, PM presence in symptomatic and asymptomatic patients with GPA, and its implications for quality of life.

Methods: Forty consecutive GPA patients fullfiling the ACR criteria and/or the 2012 Chapel Hill Consensus Conference definition were studied. After informed consent, gadolinium-enhanced brain MRI in search of PM, irrespective of CNS symptoms, was done. The presence of diffuse or focal meningeal enhancement was necessary for PM diagnosis. Main subgroups for analysis were formed according to two main criteria: PM on MRI, and CNS symptoms presence or absence. They were compared regarding clinical, serological, neuroimaging and treatment-related findings. Functional status was assessed with the Short Form 36 (SF-36) health survey and Karnofsky Performance Scale Index. Univariate analysis was used to establish proportions with means ± SD and medians calculated; bivariate analysis was used to compare groups, Student’s t test for continuous variables and X2 test with Yates correction for categorical variables. Significance was established when p<0.05.

Results: Ten patients had generalised disease, the rest localised. Age range was 8-72 years old. Main differences regarding PM and CNS symptomatology as related to MRI findings are shown in the table.

Significant differences according to presence of CNS symptoms

Variable

Symptomatic (n-20)

Asymptomatic (n-20)

p value

Cranial nerve palsy

5/20

0/20

<0.009

PM

13/20

6/20

0.05

Severely active disease *

9/20

0/20

0.001

Remission (at time of MRI)

3/20

17/20

0.001

Visual analogue scale (VAS) ♯

 3.61 ± 2.3

0.6 ± 1.2

<0.009

Significant differences according to PM in MRI

Variable

PM present (n-19)

PM absent (n-21)

p value

Cranial nerve palsy

5/19

0/21

0.02

Myalgias

4/19

0/21

0.04

Severely active disease

9/19

0/21

<0.009

Remission

4/19

15/21

0.003

BVAS-WG ♯

2.7 ± 2.7

0.1 ± 0.5

0.002

SF-36 §

21.5 (0-65)

50 (43-60)

0.001

Subglottic stenosis (SGS)

3/19

14/21

0.002

* Defined as that compromising life or vital organ function; ♯ mean values ± SD; § median values (intervals)

Conclusion: We found PM in 19/40 cases (47.5%) and irrespective of symptoms it was present in 1/3 of cases. Its cause (active disease or chronic inflammation, possibly due to fibrosis) is difficult to discern. Therefore, optimal therapeutic measures are unknown. Although the majority of patients had localised -predominant upper airway and ocular- disease, SGS had developed in a minority of patients with PM. This may suggest that operative mechanisms differ in both locations, and although scarring has been considered to play a role in PM in GPA, it might not be exclusive. Certain features relate straightforwardly to better health status, but in those asymptomatic PM patients, we found lower SF-36 scores, implying impaired quality of life. That PM occurs frequently in localised disease does not mean less severity than generalised malady. Although limited by the small sample size, CNS involvement detection in GPA, even in absence of symptoms, could be useful as impairment in quality of life may occur. Further research on this issue is warranted, with proper placement of early neuroimaging.


Disclosure: V. Higuera-Ortiz, None; N. Ruiz, None; D. Carrillo, None; A. Reynoso, None; R. D. Delgado-Hernández, None; L. F. Flores-Suarez, None.

To cite this abstract in AMA style:

Higuera-Ortiz V, Ruiz N, Carrillo D, Reynoso A, Delgado-Hernández RD, Flores-Suarez LF. MRI Findings in Granulomatosis with Polyangiitis: Pachymeningitis and Implications in Quality of Life [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/mri-findings-in-granulomatosis-with-polyangiitis-pachymeningitis-and-implications-in-quality-of-life/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mri-findings-in-granulomatosis-with-polyangiitis-pachymeningitis-and-implications-in-quality-of-life/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology